LMY 232
Alternative Names: LMY-232Latest Information Update: 30 Mar 2021
At a glance
- Originator Luminary Therapeutics
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Cell replacements; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours